GB9816046D0 - Safety enhancing pharmeceutical compositions - Google Patents

Safety enhancing pharmeceutical compositions

Info

Publication number
GB9816046D0
GB9816046D0 GBGB9816046.8A GB9816046A GB9816046D0 GB 9816046 D0 GB9816046 D0 GB 9816046D0 GB 9816046 A GB9816046 A GB 9816046A GB 9816046 D0 GB9816046 D0 GB 9816046D0
Authority
GB
United Kingdom
Prior art keywords
safety enhancing
pharmeceutical
compositions
pharmeceutical compositions
enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GBGB9816046.8A
Other versions
GB2325409B (en
GB2325409A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REDPATH TREVOR H
Original Assignee
REDPATH TREVOR H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by REDPATH TREVOR H filed Critical REDPATH TREVOR H
Priority to GB9816046A priority Critical patent/GB2325409B/en
Publication of GB9816046D0 publication Critical patent/GB9816046D0/en
Publication of GB2325409A publication Critical patent/GB2325409A/en
Application granted granted Critical
Publication of GB2325409B publication Critical patent/GB2325409B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GB9816046A 1994-06-28 1994-06-28 Pharmaceutical use of ondansetron/cyclodextrin complexes Expired - Fee Related GB2325409B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9816046A GB2325409B (en) 1994-06-28 1994-06-28 Pharmaceutical use of ondansetron/cyclodextrin complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9816046A GB2325409B (en) 1994-06-28 1994-06-28 Pharmaceutical use of ondansetron/cyclodextrin complexes
GB9412950A GB2290963A (en) 1994-06-28 1994-06-28 Pharmaceutical uses of ondansetron

Publications (3)

Publication Number Publication Date
GB9816046D0 true GB9816046D0 (en) 1998-09-23
GB2325409A GB2325409A (en) 1998-11-25
GB2325409B GB2325409B (en) 1999-02-10

Family

ID=10757437

Family Applications (4)

Application Number Title Priority Date Filing Date
GB9822734A Withdrawn GB2327348A (en) 1994-06-28 1994-06-28 Pharmaceutical use of ondansetron
GB9816045A Expired - Fee Related GB2325408B (en) 1994-06-28 1994-06-28 Chewing gum formulation comprising ondansetron
GB9412950A Withdrawn GB2290963A (en) 1994-06-28 1994-06-28 Pharmaceutical uses of ondansetron
GB9816046A Expired - Fee Related GB2325409B (en) 1994-06-28 1994-06-28 Pharmaceutical use of ondansetron/cyclodextrin complexes

Family Applications Before (3)

Application Number Title Priority Date Filing Date
GB9822734A Withdrawn GB2327348A (en) 1994-06-28 1994-06-28 Pharmaceutical use of ondansetron
GB9816045A Expired - Fee Related GB2325408B (en) 1994-06-28 1994-06-28 Chewing gum formulation comprising ondansetron
GB9412950A Withdrawn GB2290963A (en) 1994-06-28 1994-06-28 Pharmaceutical uses of ondansetron

Country Status (1)

Country Link
GB (4) GB2327348A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
DE102010024050B4 (en) 2010-06-16 2014-12-31 Magna Car Top Systems Gmbh Moving roof for a passenger car
CN103919052A (en) * 2014-01-21 2014-07-16 中国人民解放军第三军医大学 Composition used for physical recovery, and its application
CA3071377C (en) * 2017-01-09 2021-11-30 Kathleen E. Clarence-Smith Compositions and methods for improving muscle weakness in patients suffering from myasthenia gravis and other myasthenic syndromes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502508A1 (en) * 1984-01-25 1985-08-14 Glaxo Group Ltd., London HETEROCYCLIC COMPOUNDS
EP0201165B1 (en) * 1985-03-14 1994-07-20 Beecham Group Plc Medicaments for the treatment of emesis
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy

Also Published As

Publication number Publication date
GB9822734D0 (en) 1998-12-16
GB9816045D0 (en) 1998-09-23
GB2325408B (en) 1999-01-27
GB9412950D0 (en) 1994-10-26
GB2327348A (en) 1999-01-27
GB2325408A (en) 1998-11-25
GB2325409B (en) 1999-02-10
GB2325409A (en) 1998-11-25
GB2290963A (en) 1996-01-17

Similar Documents

Publication Publication Date Title
EG20753A (en) Synergistic composition
ZA957233B (en) Topically-effective compositions
EG20929A (en) Cleasing compositions
GB9408545D0 (en) Compositions
GB9417524D0 (en) Pharmaceutical compositions
EP0755250A4 (en) Benzamide-containing pharmaceutical compositions
HU9600207D0 (en) Vaccine compositions
GB9418609D0 (en) Pharmaceutical compositions
GB9424908D0 (en) Anti-Oxidant Compositions
GB9409543D0 (en) Compositions
GB9502770D0 (en) Amine-curable compositions
ZA954709B (en) Mineral-fiber compositions
GB2290299B (en) Anti-lubricant compositions
GB9816046D0 (en) Safety enhancing pharmeceutical compositions
GB9406835D0 (en) Pharmaceutical compositions
GB2295825B (en) Pharmaceutical compositions
GB9416768D0 (en) Compositions
EP0705632A3 (en) 2-Methylpropenyl-terminated polyisobutylene-polydimethyl-siloxane compositions
GB9400047D0 (en) Pharmaceutical compositions
GB9315223D0 (en) Intumescent compositions
GB9416767D0 (en) Compositions
GB9822737D0 (en) Safety enhancing pharmaceutical compositions
GB9422980D0 (en) Safety against aircrash
ZA952609B (en) Safety rimlock arrangement
GB9601739D0 (en) Vaccine Compositions

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20000628